⚕ GalenOps field
←

SITE009-0428

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2023-08-17

AEs
8
Serious
0
Dropout signal
–

Adverse events

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-03 (study day 9); relationship: not assessed

severe assessed

Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-09-10 (study day 16); relationship: N

mild assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-10-02 (study day 38); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-10 (study day 138); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-13 (study day 172); relationship: Y

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-02-17 (study day 176); relationship: N

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-03-27 (study day 215); relationship: N

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-07-30 (study day 340); relationship: not assessed

Data queries

No data queries.